Literature DB >> 8384116

Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent.

E Fride1, R Mechoulam.   

Abstract

Anandamide (arachidonylethanolamide) is a brain constituent which binds to the cannabinoid receptor. We now report the first in vivo examination of this ligand. Anandamide administered i.p. in mice, caused lowering of activity in an immobility and in an open field test, and produced hypothermia and analgesia. These effects parallel those caused by psychotropic cannabinoids.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8384116     DOI： 10.1016/0014-2999(93)90468-w

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN： 0014-2999            Impact factor:   4.432


  64 in total

1.  Nonclassical and endogenous cannabinoids: effects on the ordering of brain membranes.

Authors:  A S Bloom; W S Edgemond; J C Moldvan
Journal:  Neurochem Res       Date:  1997-05       Impact factor: 3.996

2.  HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid.

Authors:  Christeene G Haj; Percy F Sumariwalla; Lumír Hanuš; Natalya M Kogan; Zhana Yektin; Raphael Mechoulam; Mark Feldmann; Ruth Gallily
Journal:  J Pharmacol Exp Ther       Date:  2015-08-13       Impact factor: 4.030

3.  Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice.

Authors:  Y Avraham; Nc Grigoriadis; T Poutahidis; L Vorobiev; I Magen; Y Ilan; R Mechoulam; Em Berry
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 4.  Cannabinoid receptors and endocannabinoids: evidence for new players.

Authors:  Ken Mackie; Nephi Stella
Journal:  AAPS J       Date:  2006-04-28       Impact factor: 4.009

5.  Thermoregulatory phenotype of the Trpv1 knockout mouse: thermoeffector dysbalance with hyperkinesis.

Authors:  Andras Garami; Eszter Pakai; Daniela L Oliveira; Alexandre A Steiner; Samuel P Wanner; M Camila Almeida; Vladimir A Lesnikov; Narender R Gavva; Andrej A Romanovsky
Journal:  J Neurosci       Date:  2011-02-02       Impact factor: 6.167

Review 6.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Sex-dimorphic psychomotor activation after perinatal exposure to (-)-delta 9-tetrahydrocannabinol. An ontogenic study in Wistar rats.

Authors:  M Navarro; P Rubio; F Rodríguez de Fonseca
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

8.  Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents.

Authors:  Garth Terry; Jeih-San Liow; Eyassu Chernet; Sami S Zoghbi; Lee Phebus; Christian C Felder; Johannes Tauscher; John M Schaus; Victor W Pike; Christer Halldin; Robert B Innis
Journal:  Neuroimage       Date:  2008-03-18       Impact factor: 6.556

9.  Novel, potent THC/anandamide (hybrid) analogs.

Authors:  Caryl Bourne; Sucharita Roy; Jenny L Wiley; Billy R Martin; Brian F Thomas; Anu Mahadevan; Raj K Razdan
Journal:  Bioorg Med Chem       Date:  2007-08-25       Impact factor: 3.641

10.  Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide.

Authors:  R G Pertwee; L A Stevenson; G Griffin
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.